Piper Jaffray analyst Danielle Brill says the nine-month functional data from three LGMD2E patients dosed with Sarepta Therapeutics' gene therapy showed improvements across all measures. The analyst found the data particularly encouraging because both older 13 year old patients with declining function showed signs of disease reversal, the four year old patient improved to "normal" on the North Star Assessment for Dysferlinopathy functional scale, and there no signs of additional safety signals after initial liver function test elevations. These data "de-risk" the entire LGMD gene therapy platform and create a possible path to accelerated approval, Brill tells investors in a research note titled "LGMD2E Gene Therapy Data Show Indisputable Functional Benefits." She keeps an Overweight rating on Sarepta shares with a $185 price target. The stock in morning trading is up 6% to $86.11.